Daiichi Sankyo Company (4568-TO)

Financial Times  May 10  Comment 
Daiichi Sankyo pays Welsh start-up £12.5m for regenerative medicine to fix damaged heart tissue
FiercePharma  Feb 12  Comment 
A parade of politicians, physicians and pundits have criticized a Super Bowl commercial intended to stimulate awareness of opioid-induced constipation, linking the campaign to the opioid prescription drug addiction problem in the U.S. and forcing...
FierceBiotech  Dec 8  Comment 
Daiichi Sankyo is closing up its German research outpost, shuttering the former U3 Pharma as it consolidates its global R&D presence.
FiercePharma  Dec 8  Comment 
It's been rough lately for Daiichi Sankyo, and now, things are going from bad to worse. The beleaguered Japanese drugmaker is shuttering its German antibody subsidiary, months after it announced that it would cut half its U.S. workforce in a bid...
Benzinga  Nov 19  Comment 
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a biotechnology company advancing novel bio therapeutics through its proprietary Anticalin® technology platform, announced today that collaborator Daiichi Sankyo Company, Limited ("Daiichi Sankyo"),...
FierceBiotech  Oct 30  Comment 
Daiichi Sankyo picked up the FDA's breakthrough therapy designation for a Phase III cancer drug, putting it in line for preferential access to agency experts as it moves toward approval.
GenEng News  Oct 19  Comment 
Daiichi Sankyo said it expects to eliminate about one-third of its U.S. workforce—1,000 to 1,200 positions nationwide—as part of a reorganization designed to cut costs and better support its portfolio of specialty drugs for indications that...
GenEng News  Sep 17  Comment 
Daiichi Sankyo plans to develop and commercialize Translational Sciences’ Phase I blood clot dissolving agent TS23 under a license agreement whose value was not disclosed. Daiichi Sankyo said it will pay Translational Sciences unspecified...

You may also be interested in articles related to Daiichi Sankyo Company (4568-TO):
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki